Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Network measures predict neuropsychological outcome after brain injury

  • Lack of facial expression leads to perceptions of unhappiness, new research shows

  • Neural compensation in people with Alzheimer's-related protein

  • Using cerebral protection device during transcatheter aortic valve replacement can cut number of cerebral lesions

  • Sport, physical activity help against depression

  • Smoking, schizophrenia linked by alterations in brain nicotine signals

  • Myth about Parkinson's disease debunked

  • Neuroimaging technique identifies concussion-related brain disease in living brain

  • Slowed processing speed linked with executive deficits in multiple sclerosis

  • Slow to mature, quick to distract: ADHD brain study finds slower development of key connections

  •